Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond, Leukemia, vol.32, pp.252-262, 2018. ,
The proteasome and proteasome inhibitors in multiple myeloma, Cancer Metastasis Rev, vol.36, pp.561-584, 2017. ,
The 26S proteasome is a multifaceted target for anti-cancer therapies, Oncotarget, vol.6, pp.24733-24749, 2015. ,
, Lancet, vol.385, issue.14, pp.60493-60494, 2015.
Resistance to proteasome inhibitors and other targeted therapies in myeloma, Br. J. Haematol, vol.182, pp.11-28, 2018. ,
Spectrum and functional validation of PSMB5 mutations in multiple myeloma, Leukemia, vol.33, pp.447-456, 2018. ,
Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits, vol.4, p.8153, 2015. ,
, , p.8467
Aggresome induction by proteasome inhibitor bortezomib and ?-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells, Blood, vol.108, pp.3441-3449, 2006. ,
Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance, Clin. Transl. Immunol, 1007. ,
Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1, Am. J. Hematol, vol.88, pp.265-272, 2013. ,
Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy, Oncotarget, vol.7, pp.56726-56736, 2016. ,
Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cells, Oncotarget, vol.7, pp.45214-45224, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01762004
Cyclin D1 sensitizes myeloma cells to endoplasmic reticulum stress-mediated apoptosis by activating the unfolded protein response pathway, BMC Cancer, vol.15, 2015. ,
Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma, J. Cell Biochem, vol.113, pp.419-425, 2012. ,
Constitutive activation of STAT3 in myeloma cells cultured in a threedimensional, reconstructed bone marrow model, Cancers, vol.10, p.206, 2018. ,
Multiple myeloma : 2016 update on diagnosis, risk-stratification and management, Am. J. Hematol, vol.91, pp.719-734, 2016. ,
Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells, Cancer Res, vol.72, pp.4562-4573, 2012. ,
Drug combination studies and their synergy quantification using the Chou-Talalay method, Cancer Res, vol.70, pp.440-446, 2010. ,
Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells, Sci. Rep, vol.7, p.13946, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01725070
The molecular classification of multiple myeloma, Blood, vol.108, pp.2020-2028, 2006. ,
Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma, Oncotarget, vol.6, pp.15410-15424, 2015. ,
Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma, J. Hematol. Oncol, vol.11, p.29, 2018. ,
Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia, Cancer Res, vol.74, pp.2520-2532, 2014. ,
Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma, Blood Cancer J, vol.9, p.95, 2019. ,
TrxR1 inhibition overcomes both hypoxiainduced and acquired bortezomib resistance in multiple myeloma through NF-?? inhibition, Cell Cycle, vol.5, pp.559-572, 2016. ,
Pellat-Deceunynck, C. Targeting oxidative stress with auranofin or Prima-1 Met to circumvent p53 or Bax/Bak deficiency in myeloma cells, Front. Oncol, vol.9, p.128, 2019. ,
HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells, Mol. Cancer Ther, vol.8, pp.2441-2451, 2009. ,
Compromising the unfolded protein response induces autophagy-mediated cell death in multiple myeloma cells, PLoS ONE, 2011. ,
Reactive oxygen species (ROS) as pleiotropic physiological signalling agents, Nat. Rev. Mol. Cell Biol, vol.2020, pp.363-383 ,
Multiple myeloma: 2020 updtate on diagnosis, risk-stratification and management, Am. J. Hematol, vol.2020, pp.548-567 ,
Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib, Br. J. Haematol, vol.141, pp.494-503, 2008. ,
Nox enzymes and new thinking on reactive oxygen: A double-edged sword revisited, Ann. Rev. Pathol, vol.9, pp.119-145, 2014. ,
The tumor microenvironment shapes hallmarks of mature B-cell malignancies, Oncogene, vol.34, pp.4673-4682, 2015. ,
Pellat-Deceunynck, C. p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell, Blood Rev, vol.31, pp.251-259, 2017. ,
Copper-zinc superoxide dismutasemediated redox regulation of bortezomib resistance in multiple myeloma, Redox Biol, vol.4, pp.23-33, 2015. ,
Kallikrein-related peptidase 6 induces chemotherapeutic resistance by attenuating auranofin-induced cell death through activation of autophagy in gastric cancer, Oncotarget, vol.7, pp.85332-85348, 2016. ,
Cystatin SN inhibits auranofin-induced cell death by autophagic induction and ROS regulation via glutathione reductase activity in colorectal cancer, Cell Death Dis, 2017. ,
Selective inhibition of endogenous antioxidants with Auranofin causes mitochondrial oxidative stress which can be countered by selenium supplementation, Biochem. Pharmacol, vol.146, pp.42-52, 2017. ,
Antioxidant defenses confer resistance to high dose melphalan in multiple myeloma cells, Cancers, vol.11, p.439, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02870153
Resistance to the proteasome inhibitors: Lessons from multiple myeloma and mantle cell lymphoma, Proteostasis and Disease ,
URL : https://hal.archives-ouvertes.fr/hal-02971497
, , vol.1233, pp.153-174
Resveratrol sensitizes carfilzomib-induced apoptosis via promoting oxidative stress in multiple myeloma cells, Front. Pharmacol, vol.9, p.334, 2018. ,